Select A Category


A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated

Protocol Chair: Samuel Jacobs, MD

Protocol Officer: Carmen Allegra, MD

Primary Objective: To determine the progression-free survival (PFS) in each of these HER2 populations.

Patient Population: "quadruple wild-type" (all RAS/NRAS/BRAF/PIK3CA wild-type), metastatic colorectal cancer based on HER2 status (amplified, non-amplified [wild-type] or mutated).

Target Accrual: 35 patients

Status: Recruiting participants

ClinicalTrials.gov Identifier: NCT03457896